No Data
No Data
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Maintain for one month! Johnson & Johnson (JNJ.US) submits new indications for anti-depressant nasal sprays.
On July 22, Johnson & Johnson (JNJ.US) announced the submission of a supplemental New Drug Application (sNDA) to the US FDA.
Time for Healthcare ETFs?
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Alvotech Launches First Biosimilar of J&J's Stelara in Europe
No Data
muhamad Hazairudin s : Muhammad Hazairudin Shadan